Compyl
GRC Your Way

How Life Sciences Companies Automate Compliance and Vendor Risk

By Compyl Research · Last reviewed November 2026

Life sciences companies automate compliance and vendor risk by running GxP and security requirements from one control library, collecting evidence from validated systems continuously, tiering suppliers such as CROs, CDMOs and SaaS vendors by their impact on product quality and data integrity, and keeping qualification records, audits and monitoring for each supplier in one place. The goal is a single program that satisfies FDA inspectors, EU GMP expectations and customer security reviews without three separate teams doing the same work.

Two regulatory shifts make this timely. In September 2025, the FDA finalized its Computer Software Assurance guidance, which supersedes the software validation section of its older General Principles of Software Validation guidance and calls for a risk-based approach to assuring production and quality system software (FDA). In July 2025, the European Commission published a draft revision of EU GMP Annex 11 that grows from 5 to 19 pages, with security, identity and access management, audit trails and supplier management among its largest topics, alongside a new Annex 22 on artificial intelligence (ECA Academy).

Key takeaways

  • GxP and security now overlap. Access control, audit trails and supplier oversight appear in Part 11, the Annex 11 draft, SOC 2 and ISO 27001 alike.
  • Risk-based is the regulator’s word, too. FDA’s CSA guidance and the Annex 11 draft both reward focusing effort where patient safety and data integrity are at stake.
  • Suppliers carry much of the risk. CROs, CDMOs, labs and cloud vendors hold regulated data and run regulated processes on your behalf.
  • Automation removes duplicate work. One control, mapped to every requirement, tested once with evidence pulled from the source system.

Which regulations and frameworks do life sciences companies manage?

Requirement What it covers What to automate
21 CFR Part 11 Electronic records and electronic signatures in FDA-regulated activities Access controls, audit trail reviews, signature controls, system inventory
FDA Computer Software Assurance (2025) Risk-based assurance for production and quality system software Risk classification of systems, assurance records, change tracking
EU GMP Annex 11 (and 2025 draft) Computerised systems in EU GMP manufacturing Supplier and service management, security, audit trails, periodic review
EU GMP Annex 22 (draft) AI models used in GMP-critical applications AI inventory, intended use, test data and acceptance records
HIPAA Protected health information, often in clinical and patient-support programs Risk analysis, business associate agreements, access reviews
SOC 2 / ISO 27001 Security assurance demanded by pharma partners and customers Continuous control monitoring and evidence collection
GDPR EU personal data, including trial participants Records of processing, vendor data processing terms, DPIAs

How do life sciences companies automate vendor risk management?

Life sciences supplier management is unusually layered. A biotech may rely on a CRO for trials, a CDMO for manufacturing, central labs, an eTMF or EDC provider, and dozens of SaaS tools that touch regulated data. Automation works best in five steps:

  1. Inventory every supplier and record what it does: GxP-relevant, handles personal or patient data, or neither.
  2. Tier by impact. Suppliers that affect product quality, patient safety or data integrity get the deepest review. Low-impact SaaS gets a lighter questionnaire.
  3. Automate due diligence. Send tier-appropriate questionnaires, collect SOC reports, ISO certificates and quality agreements, and score responses consistently.
  4. Monitor between reviews. Track certificate expiries, breach news and changes in a supplier’s posture, and reassess on a schedule set by tier.
  5. Roll findings into the risk register. A supplier issue should appear next to the internal risks and controls it affects, so quality and security leaders see one picture.
Life sciences supplier risk workflow: inventory, tier by impact on quality and data integrity, due diligence, continuous monitoring and roll-up into the risk register

What to automate first

Teams that try to automate everything at once stall. A sensible order:

  • Access reviews for validated and regulated systems. They are high-frequency, required by almost every framework and easy to pull from identity providers.
  • Supplier inventory and tiering. Without it, nothing else in vendor risk can be prioritized.
  • Evidence for overlapping controls. Access, change management, backup and training evidence serve Part 11, Annex 11, SOC 2 and ISO 27001 together.
  • Audit trail and periodic review tracking. Both feature heavily in the Annex 11 draft and in FDA inspections.

Where Compyl fits

Compyl gives life sciences teams one place to run security compliance, GxP-adjacent controls and supplier risk together. A single control library is cross-mapped across 70+ frameworks, so access and change-management evidence collected once supports several requirements. Third-party risk management covers inventory, tiering, due diligence questionnaires, Third Party Insights and continuous scoring, and supplier findings roll into the enterprise risk register. Evidence Studio pulls live proof from 125+ in-house integrations, and configurable workflows fit quality and IT approval chains. Book a demo or read our guide to third-party risk management in healthcare.

Life sciences compliance FAQs

How do life sciences companies automate compliance and vendor risk management?

They run GxP and security requirements from one cross-mapped control library, pull evidence automatically from regulated systems, tier suppliers by impact on product quality and data integrity, automate due diligence and monitoring, and roll supplier findings into a single risk register.

What is FDA Computer Software Assurance?

Computer Software Assurance (CSA) is FDA guidance, finalized in September 2025, describing a risk-based approach to establishing confidence in production and quality system software. It supersedes Section 6 of FDA’s General Principles of Software Validation guidance.

What is changing in EU GMP Annex 11?

A draft revision published in July 2025 expands Annex 11 from 5 to 19 pages, with much greater emphasis on security, identity and access management, audit trails and supplier and service management. A separate draft Annex 22 addresses AI in GMP settings.

How should life sciences companies tier their vendors?

By impact. Suppliers that affect product quality, patient safety or the integrity of regulated data, such as CROs, CDMOs and validated software providers, get the deepest due diligence and most frequent review. Low-impact vendors get lighter questionnaires and longer review cycles.

Do life sciences companies need SOC 2 or ISO 27001?

Many do, especially biotech platforms, digital health companies and service providers selling to pharma, because customers and partners ask for independent security assurance in addition to GxP compliance.

By clicking “Accept”, you agree to the use of cookies on your device in accordance with our Privacy and Cookie policies